A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)
NCT04557150
Age 18 +
Sex Both
Phase
Third Opinion Trial Synopsis
In this study, a new medicine called RO7425781 will be given to people with a type of cancer called r/r MM who cannot be helped by usual treatments or who are not able to tolerate them. The study has two parts: first, doctors will give different amounts of RO7425781 to find out the best dose; then, they will test that dose against another treatment to see how well it works.
In this study, a new medicine called RO7425781 will be given to people with a type of cancer called r/r MM who cannot be helped by usual treatments or who are not able to tolerate them. The study has two parts: first, doctors will give different amounts of RO7425781 to find out the best dose; then, they will test that dose against another treatment to see how well it works.
Third Opinion AI Generated Synopsis
Trial Summary
This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy, dose-escalation and dose expansion study. Forimtamig will be administered to participants with r/r MM for whom no standard-of-care treatment exists or who are intolerant to those established therapies. The study consists of two parts: dose-escalation of forimtamig (Part 1) and a randomized dose expansion of forimtamig (Part 2).
This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy, dose-escalation and dose expansion study. Forimtamig will be administered to participants with r/r MM for whom no standard-of-care treatment exists or who are intolerant to those established therapies. The study consists of two parts: dose-escalation of forimtamig (Part 1) and a randomized dose expansion of forimtamig (Part 2).
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
